d4T


Also found in: Medical, Acronyms, Wikipedia.

d4T

 (dē′fôr′tē′)
n.

[d(i)d(ehydro)-d(i)d(eoxy)t(hymidine).]
Mentioned in ?
References in periodicals archive ?
For patients who were receiving d4T, 3TC and EFV who have a detectable VL, clinicians should do additional adherence counselling and repeat the VL in 2-3 months.
With the decreasing use of d4T and ddI due to the availability of tenofovir, lactate-related problems are becoming rarer, but clinical sensitivity to this possible fatal side-effect needs to remain high.
Drugs: Twenty tablets/capsules of NVP (Nevirex 200, Aurobindo Pharma Limited, India), 3TC (Lamivox 150, Aurobindo Pharma Limited, India), d4T (Stavir 30, Cipla, India) each were analysed for their drug content by HPLC and spectrophotometric methods.
In 2 cases NVP was switched to EFV following the initiation of TB treatment, and d4T was substituted for AZT in 1 case following diagnosis of hepatitis.
In the Australian MITOX study, 111 HIV-positive patients with evidence of fat-wasting from the limbs and who were taking a HAART regimen including AZT or d4T, were randomly allocated to either switch the thymidine analogue for ABC or remain on AZT or d4T.
Among the patients, 154 were on regimens that also included Combivir, and 180 were on regimens containing ddI and d4T.
Another team at the Montefiore Medical Center in the Bronx, NY, compared body fat changes in a group of 120 women and concluded that use of d4T and being white or Latina was an independent risk factor for increased truncal fat and peripheral fat loss.
Krisana Kraisintu, director of the research-and-development institute at the Government Pharmaceutical Organization (GPO), said the institute took two and a half years to develop the formula for d4T, which will be marketed at 8 baht ($0.
Therefore, for those patients receiving stavudine (d4T), 3TC and EFV, switching to the FDC treatment can be considered as a single drug switch from d4T to TDF because 3TC and FTC are considered to be equivalent.
According to the WHO, d4T is still used in more than half of treatment programmes in low- and middle-income countries.
The aim of the present study was to examine the influence of immunological status, sex, BMI and dose of d4T on the steady state pharmacokinetics of 3TC and d4T in HIV-infected patients on treatment with FDCs in India.